https://www.tipranks.com/news/the-fly/veeva-price-target-raised-to-245-from-240-at-scotiabank Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price ...
Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP ...
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation ...
University of Washington & UDN Research: Demonstrated PacBio’s ability to simultaneously analyze the genome, methylome, epigenome, and transcriptome, providing novel insights into a rare and ...
Hosted on MSN1mon
5 US Longevity and Anti-aging Stocks to Watch in 2025PacBio’s sequencing products are also helping ... These programs are based on its TRACER AAV capsid discovery platform, an RNA-based screening platform that speeds up the discovery time for ...
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback